Groundbreaking

We are curious, fast and brave. We are scientific experts who want to improve the lives of patients. We rely on our outstanding scientific know-how, our leading antibody technology and novel therapeutic approaches to discover, develop and deliver transformative therapies for people who are impacted by cancer and autoimmune diseases.

Reliable

We are a reliable partner committed to the highest quality in everything we do. We provide top-quality products and services and are dedicated to excellence and safety in all processes of our value chain. We are fully aware that we bear a great responsibility.

Dedicated

We firmly believe that advanced antibody-based therapies are a key to treating cancer and autoimmune diseases. We love science, but even more so, we love helping patients who are impacted by these diseases. Every day we come to work driven to make a difference.

The patient in mind

Being able to help patients, give them hope and provide them with the best treatment available is our strongest motivation. Therefore, everything we do, every product, process, contact and service, needs to be of the highest quality to meet patients’ needs.


29/11/2021
MorphoSys AG: Corporate Calendar 2022
10/11/2021
MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results
09/11/2021
MorphoSys Announces Departure of Roland Wandeler


MorphoSys
as a Partner

Visit

Company calendar

Date
Title
Add to Calendar
  1. 03/16/2022

    Year-End Results 2021

  2. 05/04/2022

    First Quarter Interim Statement 2022

  3. 05/18/2022

    Annual General Meeting 2022

  4. 08/03/2022

    Half-Year Report 2022

  5. 11/16/2022

    Third Quarter Interim Statement 2022

Upcoming conferences

Mon
06
'21
Dec

JMP Securities Hematology and Oncology Summit

virtual
Thu-Tue
09-14
'21
Dec
Dec

American Society of Hematology

Atlanta, Georgia, USA
Thu
09
'21
Dec

Berenberg Corporate Conference

virtual
Wed
16
'22
Mar

Year-End Results 2021

Wed
04
'22
May

First Quarter Interim Statement 2022

Wed
18
'22
May

Annual General Meeting 2022

Wed
03
'22
Aug

Half-Year Report 2022

Wed
16
'22
Nov

Third Quarter Interim Statement 2022


Stock information